Skip to main content
JUBILANT PHARMOVA LIMITED logo

JUBILANT PHARMOVA LIMITED — Investor Relations & Filings

Ticker · JUBLPHARMA ISIN · INE700A01033 LEI · 335800C6LDKWF4HQH833 BSE.NS Manufacturing
Open in API
Filings indexed 1,045 across all filing types
Latest filing 2024-01-23 Regulatory Filings
Country IN India
Listing BSE.NS JUBLPHARMA

About JUBILANT PHARMOVA LIMITED

https://www.jubilantpharmova.com/

Jubilant Pharmova Limited is an integrated global pharmaceutical company operating through three primary segments: Pharmaceuticals, Contract Research and Development Services (CRDS), and Proprietary Novel Drugs. The Pharmaceuticals segment specializes in radiopharmaceuticals for nuclear medicine, allergy immunotherapy, and the development and manufacturing of generic formulations. It also provides Contract Development and Manufacturing Organization (CDMO) services for sterile injectables and non-sterile products. The CRDS division offers comprehensive drug discovery and development solutions to biopharmaceutical companies worldwide. Furthermore, the Proprietary Novel Drugs segment focuses on creating innovative therapies for oncology and autoimmune diseases. The company leverages its advanced manufacturing infrastructure and research capabilities to serve global markets with a focus on complex chemistry and specialized healthcare solutions.

Recent filings

Filing Released Lang Actions
Board Meeting — JUBILANT PHARMOVA LIMITED has informed the Exchange about Board Meeting to be held on 02-Feb-2024 to inter-alia consider and approve the Unaudited Financial results of the Company for…
Regulatory Filings
2024-01-23 English
Board Meeting — Financial Results
Board/Management Information Classification · 95% confidence The document is a short notice informing stock exchanges about an upcoming Board Meeting scheduled for February 2, 2024, where the company will consider unaudited financial results for the quarter and nine months ended December 31, 2023. It is an intimation of a board meeting rather than the meeting minutes or the financial results themselves. The document references Regulation 29 of the SEBI Listing Obligations, which pertains to board meeting disclosures. The document length is only 1170 characters, indicating it is a brief announcement rather than a full report. Therefore, this fits the category of Board/Management Information (MANG), which covers announcements of board meetings and related management information.
2024-01-23 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding compliance with SEBI regulations about a lost share certificate. It informs about the loss of a share certificate and the request for issuance of a duplicate certificate. There is no financial data, no report attached or referenced, and no mention of financial results or management changes. The content is a regulatory compliance announcement related to share certificates, which does not fit into financial reports or management announcements. It is best classified as a Regulatory Filing (RNS) as a general regulatory announcement under SEBI rules.
2024-01-17 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding compliance with SEBI regulations about a lost share certificate. It informs about the loss of a share certificate and the request for issuance of a duplicate certificate. There is no financial data, no report attached or referenced beyond this notification, and the document is short (1927 characters). It is an official regulatory announcement related to share certificates and compliance, not a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-01-15 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate issued under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming the cancellation and dematerialization of physical share certificates for the quarter ended December 31, 2023. It is addressed to stock exchanges and the company secretary, and it is a compliance certificate related to share dematerialization. The document is short (2917 characters) and primarily serves as a regulatory compliance certificate rather than a financial report or announcement of financial results. It does not contain financial statements, management discussion, or other report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory compliance documents that do not fit other specific categories.
2024-01-10 English
Acquisition
Capital/Financing Update Classification · 95% confidence The document is a disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It details the approval by the Fund Raising Committee of Jubilant Pharmova Limited for an investment and acquisition of up to 19.89% stake in O2 Renewable Energy XVI Private Limited. The document includes specifics about the acquisition, such as the nature of the target entity, consideration, percentage of shareholding acquired, and terms of the agreement. This type of disclosure is related to capital raising or financing activities, specifically an investment and share subscription. It is not a full financial report, earnings release, or management discussion, but an update on a financing/capital transaction. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support this classification with high confidence.
2024-01-02 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.